Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels

  • 18 Accesses

  • 4 Citations

Summary

Immunosuppressive acidic protein (IAP) has been described as a tumor marker in a number of malignant diseases. To evaluate the clinical importance of IAP in breast cancer patients, IAP serum level was determined in 75 breast cancer patients, using single radial immunodiffusion. Serum samples were also tested for CA 15-3. Cut off value for IAP was determined according to IAP serum level in 50 patients with benign, non inflammatory, diseases, and was set as 725 microgram/ml. Mean IAP serum level (623 mcg/ml) and positivity rate (20%) in 24 breast cancer patients with active disease were similar to those in 51 breast cancer patients with no evidence of disease (590 mcg/ml and 18%). The mean CA 15-3 serum level and positivity rate were significantly higher in patients with active disease (200 units/ml, 67%), compared to patients with no evidence of disease (18.3 units/ml, 6%). In our experience IAP was not found to be an effective tumor marker in breast cancer.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Rudman D, Treadwell PE, Josfer WRet al.: An abnormal orosomocoid in the plasma of patients with neoplastic disease. Cancer Res 32: 1951–1959, 1972

  2. 2.

    Tamura K, Shibata Y, Matsuda Yet al.: Isolation and characterization of IAP from ascitic fluids of cancer patients. Cancer Res 41: 3244–3252, 1981

  3. 3.

    Ward AM, Cooper EH, Turner Ret al.: Acute phase reactant protein profile: an aid to monitoring large bowel cancer by CEA and serum enzymes. Br J Ca 35: 170–178, 1977

  4. 4.

    Terazawa A, Tanaka N, Senou Net al.: Natural killer activity of peripheral blood lymphocytes and its relation to histopathological factors of lung cancer. Japanese J Surg 17: 236–42, 1987

  5. 5.

    Hollinshead AC, Chuang CY, Cooper EHet al.: Interrelationship of prealbumin and alpha 1 acid glycoprotein in cancer patient sera. Cancer 40: 2993–2998, 1977

  6. 6.

    Mogensen O, Mogensen B, Jakobsen Aet al.: Alpha 1 AG in ovarian cancer with a reference to IAP and CA 125. Cancer 64: 1867–1871, 1989

  7. 7.

    Mogensen O, Mogensen B: Tumor markers in ovarian cancer: A comparison between IAP and alpha 1 acid glycoprotein. Am J Obs Gyn 154: 1165–1166, 1986

  8. 8.

    Mancini G, Carbonara AO, Heremans JFet al.: Immunochemical quantitation of antigen by single radial immunodiffusion. Immunochemistery 2: 235–254, 1965

  9. 9.

    Negishi Y, Furukawa T, Oka Tet al.: Clinical use of CA 125 and its combination assay with other tumor markers in patients with ovarian carcinoma. Gyn Obst Invest 23: 200–207, 1987

  10. 10.

    Gluck S, Koster W: IAP in malignant diseases - clinical relevance? Cancer 67: 610–612, 1991

  11. 11.

    Sawada M, Okudaira Y, Matsui Yet al.: Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 52: 2081–2085, 1983

  12. 12.

    Sawada M, Okudaira Y, Matsui Yet al.: IAP in patients with gynecologic cancer. Cancer 54: 652–656, 1984

  13. 13.

    Koebl H, Tatra G, Bieglmayer Cet al.: A comparative study of IAP, CA-125 and acute phase proteins as parameters for ovarian cancer monitoring. Neoplasma 35: 215–220, 1988

  14. 14.

    Yamashita K, Hayashi H, Mure Ket al.: Serum IAP in patients with gynecologic malignancies and in pregnant women. Cancer 57: 69–74, 1986

  15. 15.

    Yabushita H, Masuda T, Ogawa Aet al.: Combination assay of CA 125, TPA, IAP, CEA and ferritin in serum for ovarian carcinoma. Gyn Oncology 29: 66–75, 1988

  16. 16.

    Shimizu Y, Oshima K, Nakano Yet al.: Significance of pregnancy associated alpha 2 glycoprotein in patients with prostate, gastric and colorectal cancer. Biken J 24: 95–102, 1981

  17. 17.

    Yamamura T, Aozasa K, Tsujimura Het al.: IAP in true histiocytic lymphoma. Cancer 60: 38–41, 1987

  18. 18.

    Tagawa S, Sawada M, Tokumime Yet al.: Serum IAP in adult T cell leukemia. Scandinavian J Hem 34: 360–369, 1985

  19. 19.

    Castelli M, Salvati F, Cruciani Aet al.: Comparative analysis of CEA and SCC serum markers with IAP in human lung cancer. Int J Biol Markers 4: 45–50, 1989

  20. 20.

    Miki T, Saiki S, Kinouchi Tet al.: IAP in patients with testicular cancer. J Uro 137: 48–52, 1987

  21. 21.

    Gohji K, Ishii M, Negata Het al.: Serum basic fetoprotein in patients with renal cell carcinoma. Cancer 65: 1405–1411, 1990

  22. 22.

    Kikuchi K, Gotoh H, Kowada Met al.: IAP in patients with brain tumors: a preliminary report. Acta Neurochirurgica 86: 42–49, 1987

  23. 23.

    Saji S, Yokoyama Y, Niwa Het al.: Clinical studies on serum IAP and ferritin in gastric cancer patients: with special reference to preoperative value and influence of surgical stress. J Surg Oncol 33: 215–222, 1986

  24. 24.

    Aozasa K, Ueda T, Ayata Met al.: Immunohistochemical determination of IAP in reactive and neoplastic diseases of macrophage. Cancer 60: 2424–2427, 1987

  25. 25.

    Castelli M, Romano P, Atlante Get al.: IAP and CA 125 assays in detection of human ovarian cancer: preliminary results. Int J Biol Markers 2: 187–90, 1987

  26. 26.

    Quaranta M, Coviello M, Lorusso Vet al.: IAP serum levels in breast cancer. J Tumor Marker Oncol 5: 191–4, 1990

  27. 27.

    Menard S, Tagliabue E, Canevari Set al.: Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res 43: 1295–1300, 1983

  28. 28.

    Hilkens J, Kroezen V, Bonfrer JMGet al.: MAM 6 antigen, a new serum marker for breast cancer monitoring. Cancer Res 46: 2582–2587, 1986

  29. 29.

    Hilkens J, Buijs F, Hilgers Jet al.: Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34: 197–206, 1984

  30. 30.

    Taylor Papadimitriou J, Peterson JA, Arklie Jet al.: Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28: 17–21, 1981

  31. 31.

    Kufe D, Inghirami Get al.: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223–232, 1984

  32. 32.

    Hayes DF, Zurawski VR, Kufe DWet al.: Comparison of circulating CA 15-3 and CEA levels in patients with breast cancer. J Clin Oncol 4: 1542–1550, 1986

  33. 33.

    Colomer R, Ruibal A, Genolla Jet al.: CA 15-3 levels in the postsurgical follow up of breast cancer patients in non malignant disease. Breast Can Res Treat 13: 123–133, 1989

  34. 34.

    Safi F, Kohler I, Rottinger Eet al.: Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 4: 207–14, 1989

  35. 35.

    Kerin MJ, McAnena OJ, OMalley VPet al.: CA 15-3: Its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 76: 838–839, 1989

  36. 36.

    Sacks NPM, Stacker SA, Thompson CHet al.: Comparison of MSA and CA 15-3 levels in the serum of patients with breast cancer. Br J Cancer 56: 820–824, 1987

  37. 37.

    Bhatavdekar JM, Trivedi SN, Shah NGet al.: Comparison of prolactin, CA 15-3 and TPA in breast carcinomas. Int J Biol Markers 4: 150–6, 1989

  38. 38.

    Kallioniemi OP, Oksa H, Aaran RKet al.: Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 58: 213–5, 1988

  39. 39.

    Barak V, Carlin D, Sulkes Aet al.: CA 15-3 serum levels in breast cancer and other malignancies-correlation with clinical course. Israel J Med Sci 24: 623–627, 1988

  40. 40.

    Iaffaioli RV, Caponigro F, Eposito Get al.: Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with TPA and CEA. Int J Biol Markers 6: 21–4, 1991

  41. 41.

    Duncan JL, Price A, Rogers Ket al.: The use of CA 15-3 as a serum tumor marker in breast carcinoma. Eur J Surg Oncol 17: 16–9, 1991

  42. 42.

    Colomer R, Ruibal A, Salvador Let al.: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674–81, 1989

  43. 43.

    Metcalfe SM, Elyan SA, Wheeler TKet al.: Tumor markers in breast cancer: a report on the extensive clinical use of B5 and CA15-3. Clin Oncol (R Coll Radiol) 2: 142–7, 1990

  44. 44.

    Zanco P, Rota G, Sportiello Vet al.: Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques. Int J Biol Markers 4: 103–5, 1989

  45. 45.

    Pons Anicet DMF, Krebs BP, Mira Ret al.: Value of CA 15-3 in the follow up of breast cancer patients. Br J Cancer 55: 567–569, 1987

  46. 46.

    Safi F, Kohler I, Rottinger Eet al.: The value of the tumor marker CA 15-3 in the diagnosing and monitoring breast cancer. Cancer 68: 574–582, 1991

  47. 47.

    Nicolini A, Colombini C, Luciani Let al.: Evaluation of serum CA 15-3 determination with CEA and TPA in the post operative follow up of breast cancer patients. Br J Cancer 64: 154–158, 1991

  48. 48.

    Cohen Y, Mohilever J: MEDATA - an interactive report generator for radiation and medical oncology services. In: Minet P (ed) Impact of Personal Computers (PC) on Radio-Oncology Departments. European Association of Radiology, 4th workshop organized by Commission Informatique, WHO Headquarters, Geneva, 1990, pp 147–153

  49. 49.

    Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

Download references

Author information

Correspondence to Yoram Cohen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cohen, A.D., Shoenfeld, Y., Gopas, J. et al. Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels. Breast Cancer Res Tr 30, 197–200 (1994). https://doi.org/10.1007/BF00666063

Download citation

Key words

  • breast cancer
  • CA 15-3
  • IAP
  • immunosuppressive acidic protein
  • tumor markers